CD274 and neoplasm: There has been a large number of biomarkers for the prediction of the responsiveness both at genome level and at transcriptome level, such as the tumor mutation burden (6), the microsatellite instability (39), the neoantigens (7, 8), the PD-L1 expression (9, 10), and the tumor immune microenvironments based on the gene expression profiles (11, 12).